Market Definition 

Immunology is a study of immune system that protects the body from infection through various lines of defence. The dysfunction in the immune system can cause immunological disorders including allergy, autoimmune diseases, asthma, autoinflammatory syndromes and cancer. The immunological disorders can be treated form monoclonal antibody (mAb), immunosuppressants, polyclonal antibody (pAb), fusion proteins, and others. 

Global immunology market is estimated to reach $XX billion by 2026; growing at a CAGR of 8.2% till 2026. 

Market Dynamics 

Rising prevalence of autoimmune and other immunological disorders are key driving factors of the market. Immunological disorders are caused by a dysfunction of the immune system including allergy, autoimmune diseases, asthma, autoinflammatory syndromes and immunological deficiency syndromes. According to the National Institutes of Health (NIH), globally, more than 700 million people, nearly one-tenth of the global population suffer from autoimmune disease. According to the American Autoimmune Related Diseases Association (AARDA), up to 50 million Americans suffer from an autoimmune disease and the prevalence is expected to rise in the coming years. According to the British Society for Immunology, more than four million people in the UK have an autoimmune condition. However, the side effect of immunotherapy might hamper market growth. The most common side effect of immunotherapy includes skin redness, blistering, dryness, fever, weakness, vomiting, nausea, body aches, dizziness, and high or low blood pressure. Moreover, increasing investment for immunotherapy would provide lucrative opportunities for the market in the coming years. 

Market Segmentation 

The global immunology market is mainly classified based on type and application. Type is further segmented into Monoclonal Antibodies (mAb), Immunosuppressants, Polyclonal Antibody (pAb), Fusion Proteins, and Others. By application, the market is divided into Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Prophylaxis of Organ Rejection, Inflammatory Bowel Disease, and Others.  

Monoclonal Antibodies (mAb) has shown significant growth in 2019, owing to the increasing commercialization of monoclonal antibody-based therapeutics, rising clinical studies on monoclonal antibody-based therapeutics, the collaboration between companies to develop and commercialize of monoclonal antibody-based therapeutics and increasing regulatory approval for monoclonal antibody-based therapeutics. For instance, AbbVie has received the U.S. Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa). SKYRIZI is an interleukin-23 (IL-23) inhibitor for the treatment of moderate to severe plaque psoriasis in adults. 

Regional Analysis 

Based on geography, the global immunology market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America was dominating the global immunology market in 2019, due to the rising incidence of autoimmune and other immunological disorders, commercialization of new immunology products, increasing clinical studies, the partnership between companies to develop and commercialize new immunology products, and government support to develop immunology products. For instance, The National Institute of Allergy and Infectious Diseases (NIAID) a part of the National Institutes of Health, has funded $30 million three institutions to provide new centers of immunology research for tuberculosis (TB) vaccine development. The three institutions include the Harvard T.H. Chan School of Public Health in Boston, the Infectious Disease Research Institute of Seattle, and the Seattle Children’s Hospital. 

Competitive landscape 

Key players operating in the immunology industry include AbbVie Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Astellas, Janssen, Novartis AG, Merck, UCB SA, Bristol-Myers Squibb, and Amgen Inc. 

The increasing commercialization of immunology products, rising clinical studies on immunology products, the partnership between companies to develop and commercialize of immunology products, increasing investment and funding by the companies to develop and commercialize immunology products and increasing regulatory approval for immunology products are some of the strategies adopted by the major companies. For instance, on March 26, 2020, Bristol-Myers Squibb Company has received the U.S. Food and Drug Administration (FDA) approval for ZEPOSIA (ozanimod) 0.92 mg for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. ZEPOSIA is an oral medication, is the only approved sphingosine-1-phosphate (S1P) receptor modulator. 

Immunology Market Key Segments: 

By Type 

• Monoclonal Antibodies (mAb) 
• Immunosuppressants 
• Polyclonal Antibody (pAb) 
• Fusion Proteins 
• Others 

By Application 

• Rheumatoid Arthritis 
• Psoriatic Arthritis 
• Ankylosing Spondylitis 
• Plaque Psoriasis 
• Prophylaxis of Organ Rejection 
• Inflammatory Bowel Disease 
• Others 

Key Global Immunology Industry Players 

• AbbVie Inc. 
• F. Hoffmann-La Roche Ltd 
• Pfizer Inc. 
• Astellas 
• Janssen 
• Novartis AG 
• Merck 
• UCB SA 
• Bristol-Myers Squibb 
• Amgen Inc. 

What Report Provides 

• Full in-depth analysis of the parent Industry 
• Important changes in market and its dynamics 
• Segmentation details of the market 
• Former, on-going, and projected market analysis in terms of volume and value 
• Assessment of niche industry developments 
• Market share analysis 
• Key strategies of major players 
• Emerging segments and regional growth potential